Excerpts

The trial showed a trend toward improved median PFS with T + E (3.8 months vs. 1.9 months, HR 0.64, p = 0.079).

We also found an increase in CD11b + granulocytes (mean difference: 11.82, 95% CI: 0.207 – 23.43, two-tailed t-test p=0.0475) in GM-CSF-treated mice ( Figure 3D , Supplementary Figure S2D ), which was generally accompanied by a strong trend toward increased neutrophils (mean difference: 13.85, 95% CI: -2.555 – 30.26, two-tailed t-test p=0.079) vs placebo-treated mice ( Figure 3E , Supplementary Figure S2E ).

Interestingly, when toripalimab was administrated two days after chemotherapy rather than being used simultaneously, the combinational neoadjuvant regime showed a trend toward a higher pCR rate (36.4%, 4/11 versus 7.7%, 1/13, P = 0.079) ( 60 ).

Moreover, the percentages of monocytes ( Figure 6C ) remained similar in Rs and NRs from baseline through day 3, then followed by a rapid elevation on day 7 in NRs with near significance ( p = 0.079).

Gender comparisons revealed that SLE females had reduced levels of EndoCAb IgM ( P = 0.008), whereas SLE males only showed a trend toward significance ( P = 0.08).

IL-1α levels showed a statistical trend for association with low IP (p-value=0.08) ( Figure 3E ) and was significantly increased in infants with less abx (p-value < 0.01) ( Figure 3F ), more MOM feed (p-value <0.05) ( Figure 3G ), and later GA (p-value < 0.01) ( Figure 3H ).

Patients developing ABMR during follow-up showed a trend towards higher amino acid MM (88±5 vs. 63±22, p=0.08); global PIRCHE-II (117±48 vs. 80±38, p=0.06) and higher eplet MM load (41.5±7 vs. 32±11, p=0.07).

Results revealed a clear trend toward a high diversity of microbial species when examining the above-mentioned consecutive samples ( p = 0.08).

Significantly decreased levels of the MoAM associated chemokines CCL2 and CCL7 (21% and 69%, respectively) and a strong trend towards decreased total BALF macrophage counts (30% decrease on average, p = 0.08) in treated animals further corroborates the anti-inflammatory effect of the IRAK4 inhibitor ( Figures 8B, C ).

In contrast, anti-GDNF antibody positivity showed a trend toward an increased risk of elevated FIB-4 index in the univariate analysis (OR 4.03 [1.00-27.13], p=0.08).

LS greater than 6 Kpa at day +14 also showed a trend toward worse OS (asHR: 2.3, 95% CI 0.9–6.0; p=0.08).

Total adipose tissue (TAT) showed a near-significant trend (OR = 1.01, 95% CI: 0.99-1.02, p = 0.080), indicating a potential but non-significant association ( Table 2 ).

Although both subgroups showed significant 2-year OS advantage, the subgroups difference tended towards significance (p=0.08) ( Supplementary Figure 5C ).

Sensitivity also showed a trend toward superiority for DL (0.77 vs 0.68, P = 0.08).

Although iNOS expression was marginally insignificant between Adv/GM-CSF treated and untreated tumors (p = 0.08).

The results indicated a marginally significant difference in HER2+ between the low-to-intermediate and high-to-very-high-risk groups ( p = 0.08), with a significant difference observed within subcategories ( p < 0.05).

As compared to smokers, non-smokers showed borderline significant higher CRP using morning ( p =0.08) and evening ( p =0.05) saliva.

Furthermore, CXCL12 showed a trend towards a shorter PFS (HR=2.30; 95% CI 0.86-5.97; p=0.08) in male patients.

OX40L was significantly lower in DHA-treated DC2s compared with the NT DC2s ( p = 0.05) and showed a trend in AA-treated DC2s ( p = 0.08) ( Table 2 and Figure 2A ).

CeMV seropositive dolphins had a marginally significant reduction in the absolute number of CD4+ helper T cells ( p = 0.08).

In agreement with earlier reports, we observed lower phagosome maturation following FcR-mediated phagocytosis in HIV infected persons compared to HIV negative subjects, although the difference was not significant but rather a strong trend ( p = 0.08 at 10 min and p = 0.06 at 120 min).

However, the SCID subtype T-, B+, NK- was more frequently associated with disseminated disease (18.8%) than localized or regional disease (0.0%), showing a trend toward significance (p = 0.080) ( Table 3 ).

Older subjects showed higher risks for musculoskeletal pain (panel B, increased risk in age groups 6-17 years, p-value = 0.02), cardiovascular symptoms (panel E, significantly higher in the 12-17 years age group, p-value = 0.003) and, with borderline significance, for sleep disorders (panel A, p=0.08) and sensory symptoms (panel F, p=0.05).

Moreover, in GDM-HBC a higher percentage of cells was positive for M1 markers CD80 and CD40, but these increases did not reach significance (Table 3 ); however, the M1 marker CD86 (Figures 4 D,H) showed a trend toward increased levels in GDM ( p = 0.08; Table 3 ).

A favorable trend in PFS was also observed (P = 0.08; HR = 0.62, 95% CI: 0.36–1.07) ( Supplementary Figure 2A ).